• pSivida Corp., of Watertown, Mass., said the UK's Medicines and Healthcare Products Regulatory Agency accepted for reivew the marketing application for diabetic macular edema (DME) drug Iluvien (fluocinolone acetonide intravitreal insert) via the European decentralized procedure. Iluvien will be indicated for vision impairment associated with chronic DME considered insufficiently responsive to other therapies.